HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

Alchemy, a developer of in-house pharmacy programs for clinics with large HIV and hepatitis C patient populations, raised $31 ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

HIV therapy protects the immune system by controlling the virus and preventing disease progression. This article takes a ...

Background: Current guidelines for the use of antiretroviral (ARV) therapy during pregnancy recommend that women be offered treatment with combination ARV therapy used in nonpregnant HIV-infected ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

The Ghana AIDS Commission (GAC) says the lack of funding can  impact negatively efforts to end AIDS as a public health threat ...

The following is a summary of “Drug-drug interactions between antiretrovirals and hormonal contraception: An updated ...

Methadone use in HIV-infected patients is common and has drug interactions with many currently approved antiretrovirals. When dolutegravir 50 mg twice daily was given with methadone, there were no ...

7 October 2024 (Lima, Peru) – New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024, the 5th HIV Research for Prevention ...